Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent
Investigational Drug Radium-223 Chloride Improved Overall Survival By 44 Percent
NKTR-102 Shows 29 Percent Response in Phase II Study
New Two-Step Matching Process Increases Success of Transplants
Weak Electromagnetic Fields Can Possibly Stabilize Tumors
One Flexible Sigmoidoscopy Can Reduce Risk by 31 Percent
Neurocognitive Deficits Affect Future Adult Employment
Smoking, Drinking Factors Affect Adherence to Preventive Regimen
Two Doses of the Vaccine Cervarix Can Be As Effective As Three
HPV-Positive Women Over 30 Should Be Retested Within Two Years
Clinical Trials Approved By NCI CTEP Last Month
Nucynta ER Approved For Managing Chronic Pain In Adults
Zofran Label Change Includes Warnings of QT Prolongation
Agency Approves Two Pairs Of Drugs and Diagnostic Tests
Adcetris Granted Approval For Hodgkin’s Lymphoma and ALCL
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”
